Neuland Laboratories stock | Growth outlook for 2026 & price target

Neuland Laboratories

BSE:524558

Rp 12.072,20

+ Rp0,20 (0,00%)

12.072,20 Rp

+Rp0,20 (0,00%)

End-of-day quote: 03/30/2026

Neuland Laboratories Stock Value

The current analyst rating for BSE:524558 is Buy.

Buy

Neuland Laboratories Company Info

EPS Growth 5Y

65,75%

Market Cap

Rp154,88 B

Long-Term Debt

Rp0,91 B

Annual earnings

05/09/2026 (E)

Dividend

Rp12,07

Dividend Yield

0,10%

Founded

1984

Industry

Health Care

Country

India

Website

Neuland Laboratories

ISIN Number

INE794A01010

Website

http://www.neulandlabs.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp18.650,00

54.49%

Last Update: 03/30/2026

Analysts: 4

Highest Price Target Rp20.836,00

Average Price Target Rp18.650,00

Lowest Price Target Rp17.325,00

In the last five quarters, Neuland Laboratories’s Price Target has risen from Rp3.596,79 to Rp5.875,00 - a 63,34% increase. Four analysts predict that Neuland Laboratories’s share price will increase in the coming year, reaching Rp18.650,00. This would represent an increase of 54,49%.

Top growth stocks in the health care sector (5Y.)

What does Neuland Laboratories do?

Neuland Laboratories Limited (Neuland) operates primarily in the pharmaceutical sector, focusing on the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates. Business Segments The company operates through two segments: Generic Drugs and Contract Manufacturing Services. Generic Drugs This segment involves the development and commercialization of APIs for generic pharmaceuticals. The company offers APIs for various therapeutic areas, including central nervo...

Neuland Laboratories Limited (Neuland) operates primarily in the pharmaceutical sector, focusing on the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates.

Business Segments

The company operates through two segments: Generic Drugs and Contract Manufacturing Services.

Generic Drugs

This segment involves the development and commercialization of APIs for generic pharmaceuticals. The company offers APIs for various therapeutic areas, including central nervous system disorders, cardiovascular diseases, and oncology. Neuland's expertise in complex and highly potent APIs distinguishes it from competitors, allowing the company to satisfy specific market needs effectively. The company also strives to keep manufacturing processes environmentally sustainable while adhering to ethical practices in all operations.

Contract Manufacturing Services

In this segment, Neuland collaborates with other pharmaceutical manufacturers to produce APIs and intermediates under contract. This partnership model has proven mutually beneficial, allowing businesses to leverage Neuland’s facilities, regulatory approvals, and market experience. The emphasis is on creating tailored solutions that meet the unique specifications and requirements of clients, ensuring quality and efficiency.

Neuland emphasizes agility within each segment, allowing for quick adaptions to market dynamics and client demands. Product innovation is a key driving force, fueled by ongoing research and development efforts. By focusing on these two primary segments, Neuland Laboratories effectively serves a diverse range of clientele while maximizing operational synergies across its offerings.

Business Strategy

The company employs a comprehensive business strategy that revolves around innovation, quality adherence, and market expansion. The primary objective is to establish a strong foothold in the global pharmaceutical market. A cornerstone of its strategy involves continuous investment in research and development to innovate new products that meet evolving market demands.

The company emphasizes regulatory compliance and quality management systems to enhance trust among clients and stakeholders. By adopting best practices and conforming to local and international regulations, Neuland positions itself as a reliable partner in drug development and manufacturing.

Market penetration strategies are implemented to gain a competitive edge. By forming strategic alliances and partnerships with key stakeholders in the pharmaceutical ecosystem, Neuland leverages collective strengths to explore new market segments.

Products and Services

The company specializes in the production of a wide range of active pharmaceutical ingredients and intermediates, tailored to serve diverse therapeutic areas. The key offerings fall under the umbrella of Generic Drugs and Contract Manufacturing Services.

Generic Drugs

Neuland manufactures APIs for various conditions, including but not limited to respiratory illnesses, cardiovascular disorders, diabetes, and oncology. The company's commitment to quality ensures that all products comply with international standards such as the US FDA, EMA, and ICH guidelines. This emphasizes reliability and safety for end-users.

Contract Manufacturing Services

The company offers contract manufacturing for leading pharmaceutical firms and biotech companies. The contract services cover the development and production of APIs, providing customized solutions specific to client needs. Neuland also engages in the process of technology transfer, whereby clients can shift manufacturing operations to Neuland’s facilities, benefiting from the company’s expertise and compliance track record.

Services provided also extend to regulatory support and consultancy, ensuring clients adhere to necessary compliance requirements throughout the product lifecycle. This comprehensive service offering positions Neuland as a one-stop solution for clients looking to optimize their pharmaceutical manufacturing efforts without compromising quality.

Geographical Markets Served

The company operates globally, with a significant presence across North America, Europe, and the Asia-Pacific region.

Customers

The company caters to a diverse clientele, including large pharmaceutical companies, biotech firms, and contract manufacturers. Specific client names are often confidential due to the proprietary nature of the pharmaceutical industry. Nonetheless, the company serves a substantial number of customers across various segments, maintaining strong relationships bolstered by its reputation for quality and regulatory compliance.

Sales and Marketing

The company employs a multi-faceted approach to sales and marketing, focusing on building long-lasting relationships with clients. The marketing strategy includes direct sales, digital marketing campaigns, and participation in industry conferences and exhibitions. The company utilizes its presence in key geographical markets to facilitate understanding of customer needs and preferences, enhancing service delivery.

Distribution channels are typically direct, facilitated through an experienced sales force that supports clients from inquiry through to after-sales service. This structured approach fosters strong customer relationships and enables Neuland to remain responsive to market dynamics.

Government Regulations

Neuland Laboratories operates within a highly regulated industry, adhering to government regulations that govern pharmaceutical manufacturing and drug safety. The company complies with local and international regulatory frameworks, including but not limited to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance ensures that all products meet rigorous safety, efficacy, and quality standards.

History

Neuland Laboratories Limited was founded in 1984. The company was incorporated in 1984.

Neuland Laboratories Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - Pharmaceutical Active Ingredients (APIs): approx. 70% - Contract Research and Development (CRO): approx. 20% - Other Services: approx. 10% **TOP 3 Markets:** - USA: approx. 50% - Europe: approx. 30% - India: approx. 10% Neuland Laboratories Limited generates the majority o...

At which locations are the company’s products manufactured?

**Production Sites:** Hyderabad, India Neuland Laboratories Limited mainly produces its products in Hyderabad, India. The company operates several production facilities there, specializing in the manufacturing of active pharmaceutical ingredients (APIs). These sites are strategically located to eff...

What strategy does Neuland Laboratories pursue for future growth?

**Revenue Growth:** Estimated 10-12% annually (2026) **Focus on R&D Investments:** Increase by 15% (2025) Neuland Laboratories Limited pursues a growth strategy that is heavily focused on research and development (R&D). The company continuously invests in the development of new active ingre...

Which raw materials are imported and from which countries?

**Main raw materials:** API intermediates, chemical reagents **Main importing countries:** China, USA, Europe Neuland Laboratories Limited is a company specializing in the production of active pharmaceutical ingredients (APIs). For the production of these APIs, the company imports various chemical...

How strong is the company’s competitive advantage?

**Market share:** 8% (estimated, 2026) **R&D expenses:** 5% of revenue (2025) **EBITDA margin:** 18% (2025) Neuland Laboratories Limited has established itself as a significant player in the pharmaceutical industry, particularly in the active pharmaceutical ingredients (APIs) sector. The...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 38% (estimated, 2026) **Insider Buys/Sells:** No significant transactions reported (2026) The institutional investor share in Neuland Laboratories Limited is estimated to be around 38%. This figure indicates that a significant portion of the shares are held by in...

What percentage market share does Neuland Laboratories have?

**Market share of Neuland Laboratories Limited:** Estimate: 3-5% (2026) **Top competitors and their market shares:** 1. **Dr. Reddy's Laboratories:** 10-12% 2. **Sun Pharmaceutical Industries:** 8-10% 3. **Cipla Limited:** 7-9% 4. **Lupin Limited:** 6-8% 5. **Aurobindo Pharma:** 5-7% 6. **Neul...

Is Neuland Laboratories stock currently a good investment?

**Revenue Growth:** 18% (2025) **EBITDA Margin:** 22% (2025) **R&D Expenses:** 7% of revenue (2025) Neuland Laboratories Limited achieved an impressive revenue growth of 18% in 2025, indicating strong demand for its pharmaceutical products and services. The EBITDA margin of 22% shows that the c...

Does Neuland Laboratories pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2026) **Dividend History:** Regular payouts over the last 5 years Neuland Laboratories Limited has consistently distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2026 is around 1.5%. This suggests...

New support ticket

Explore

Neuland Laboratories Stock Value

Neuland Laboratories Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neuland Laboratories do?

Neuland Laboratories Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Neuland Laboratories Stock Value

Neuland Laboratories Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neuland Laboratories do?

Neuland Laboratories Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.